Table-1:

Summary of Preclinical Studies:

Tx	Model	Results	Ref
Everolimus + gemcitabine	MIAPaCa / Panc-1	Combo had an additive anti-proliferative effect.	19
EGFR and PI3K/AKT/mTOR pathway inhibitors	GS MIAPaCa-E vs GR MIAPaCa-M	GR – insensitive to EGFR, AKT, and PI3K inhibitors. Hypersensitive to everolimus.	20
Everolimus and sorafenib	MIAPaCa-2 and Panc-1	Combination of the 2 reduced anti-proliferative versus monotherapy.	21
AZD8055 vs everolimus	PANC-1, AsPC-1, CFPAC-1, Capan-1, Capan-2, Mia-Paca2	Neither everolimus nor AZD8055 could arrest the cell cycle at the G0/G1 phase.	23
Everolimus + sorafenib	PDAC xenografts	Combo demonstrated efficacy at higher dose versus monotherapy.	24
AZD8055 + radiation	PDAC xenografts	Combo has greater efficacy than single agent.	29
Trametinib (MEK inhibitor) + everolimus	PDAC xenografts	Combo is synergistic	30

GR: gemcitabine resistant; PDAC: Pancreatic ductal adenocarcinoma.